Elevance Health Earnings Reports

Elevance Health posted strong Q3 2025 results with a 12% increase in revenue and a 17% rise in net income. Performance was supported by growth in Medicare Advantage and CarelonRx, partially offset by Medicaid headwinds and increased benefit expenses.

Elevance Health delivered strong revenue growth in Q2 2025, driven by acquisitions and Medicare Advantage membership gains, but elevated medical cost trends in ACA and Medicaid weighed on margins and net income.

Elevance Health delivered a strong start to 2025 with 15.4% revenue growth, driven by higher premium yields, acquisitions, and expanding Medicare Advantage and ACA memberships. EPS and net income remained stable, while Carelon posted significant year-over-year growth.

Elevance Health reported a 0.9% increase in operating revenue to $42.3 billion for Q1 2024, with diluted EPS up 15.5% to $9.59 and adjusted diluted EPS up 12.5% to $10.64. The company has raised its full-year earnings guidance and is launching a strategic partnership to advance primary care and physician enablement.

Elevance Health reported Q4 2023 operating revenue of $42.5 billion, a 7.0% increase year-over-year. GAAP diluted EPS was $3.63, up 1.1%, and adjusted diluted EPS was $5.62, up 15.2%. The company projects FY 2024 GAAP diluted EPS and adjusted diluted EPS of greater than $34.29 and $37.10 per share, respectively.

Elevance Health reported a solid third quarter with adjusted net income of $8.99 per share and operating revenue of $42.5 billion. The company is increasing its full-year earnings outlook based on year-to-date outperformance.

Elevance Health reported a strong Q2 2023, with a 12.7% year-over-year increase in operating revenue to $43.4 billion and a 12.0% increase in operating gain to $2.6 billion. GAAP net income was $7.79 per share, and adjusted net income was $9.04 per share. Medical enrollment increased to 48.0 million members.

Elevance Health reported a strong start to 2023, with a 10.6% year-over-year increase in operating revenue to $41.9 billion and a 16.6% increase in operating gain to $2.8 billion. Adjusted net income was $9.46 per share, and medical enrollment reached 48.1 million members.

Elevance Health reported Q4 2022 results with $39.7 billion in operating revenue and adjusted EPS of $5.23. The company's medical membership reached 47.5 million, driven by growth in both Government and Commercial & Specialty Business segments.

Elevance Health reported a strong third quarter in 2022, with an 11.5% increase in operating revenue to $39.6 billion. GAAP net income was $6.68 per share, and adjusted net income was $7.53 per share. Medical enrollment reached 47.3 million members, a 2.2 million increase year-over-year.

Elevance Health's Q2 2022 results showcased strong financial performance with double-digit growth in revenue, operating earnings, and adjusted earnings per share. The company reported an increase in medical enrollment and has raised its outlook for 2022 earnings per share.

Anthem, Inc. reported fourth quarter and full year 2021 results reflecting strong financial performance, including double-digit top and bottom line growth. Fourth quarter operating revenue grew by 14.2% to $36.0 billion, and medical enrollment increased by 303 thousand members to 45.4 million members.

Anthem, Inc. reported a strong third quarter in 2021, with a 16.0% increase in operating revenue to $35.5 billion and a rise in medical enrollment by 2.4 million members year over year to 45.1 million members. GAAP net income was $6.13 per share, and adjusted net income was $6.79 per share. The company also raised its full-year adjusted net income outlook.

Anthem, Inc. reported a 14.1% increase in operating revenue to $33.3 billion and GAAP net income of $7.25 per share for the second quarter of 2021. Medical enrollment reached 44.3 million members, and the company raised its full-year adjusted net income outlook to greater than $25.50 per share.

Anthem's first quarter 2021 results reflected strong financial performance with operating revenue growth of 9.0% to $32.1 billion and adjusted net income of $7.01 per share. Medical enrollment increased to 43.5 million members. The company raised its full year adjusted net income outlook to greater than $25.10 per share.

Anthem, Inc. reported a solid fourth quarter in 2020, marked by a 16.2% increase in operating revenue to $31.5 billion, driven by growth in Medicaid and Medicare, as well as pharmacy product revenue and the return of the health insurance tax. GAAP net income per share was $2.19, with an adjusted net income per share of $2.54. Medical enrollment reached 42.9 million members, a 4.7% increase year-over-year.

Anthem, Inc. reported a Q3 2020 operating revenue of $30.6 billion, up 15.9% year-over-year, driven by growth in Medicaid and Medicare. Medical enrollment totaled approximately 42.6 million members. GAAP net income was $0.87 per share, and adjusted net income was $4.20 per share.

Anthem reported a strong second quarter with significant growth in operating revenue and adjusted net income per share, driven by pharmacy product revenue and growth in Medicaid and Medicare. The company also saw a decrease in the benefit expense ratio due to the deferral of healthcare utilization during the COVID-19 pandemic.

Anthem, Inc. reported a strong first quarter, marked by a 20.7% increase in operating revenue to $29.4 billion, driven by pharmacy product revenue from IngenioRx and higher premium revenue. Medical enrollment reached 42.1 million members, a 3.2% increase year-over-year. The company is focused on increasing access and coverage, adapting tools and policies, leveraging data analytics, and delivering outreach and relief during the COVID-19 pandemic.

Anthem, Inc. reported a strong fourth quarter and full year 2019, marked by double-digit revenue and earnings growth. The successful launch of IngenioRx and significant organic risk-based growth contributed to the positive results. The company's medical enrollment reached 41 million lives, and operating revenue increased by 16.4% year-over-year to $27.1 billion.